Researchers at the University of California San Diego School of Medicine have identified a promising new precision therapy for triple-negative breast cancer (TNBC), one of the most aggressive and hardest-to-treat forms of the disease.
Their innovative approach uses an antibody-drug conjugate (ADC)—a targeted delivery system that directs powerful chemotherapy straight into cancer cells while sparing healthy tissue. Because ADCs can safely transport chemotherapy agents that are otherwise too toxic for direct use, they open a critical pathway for treating highly resistant cancers. The team published its findings in the Proceedings of the National Academy of Sciences.
Why Triple-Negative Breast Cancer Remains Difficult to Treat
TNBC accounts for roughly 10–15% of all breast cancer cases. In 2025 alone, experts estimate that 316,950 women and 2,800 men will receive diagnoses of invasive breast cancer. TNBC stands out as particularly challenging because it grows and spreads more rapidly than other subtypes. Moreover, it does not respond to hormonal or targeted therapies commonly used in other breast cancers.
As a result, survival rates tend to be lower, and the disease disproportionately affects younger women, Black women, and individuals with specific genetic mutations. Midway through the study, the researchers noted, as per Medical Xpress that these disparities underscore the urgent need for more precise treatment strategies.
Key Discoveries Driving the New Approach
The new study highlights several important breakthroughs:
- FZD7, a cell-surface protein, appears on TNBC cells with high tumor-initiating potential.
- When researchers engineered an ADC to target FZD7-positive cells, they significantly reduced tumor growth in mouse models without observable toxicity.
- In mouse-derived organoids, or 3D mini-tissue structures, FZD7-positive cells behaved more aggressively but also responded more effectively to the therapy.
- The treatment also worked in human TNBC cell lines, strengthening the potential for clinical relevance.
What These Findings Mean for Future Treatment
Although additional research is necessary before this therapy reaches clinical use, the results strongly suggest that targeting tumour-initiating cells through FZD7 could offer a powerful new option for patients whose cancers do not respond to current treatments. This precision-driven method may ultimately lead to more effective therapies for TNBC and, potentially, for other cancers with similar biological profiles.
The study was led by Dennis A. Carson, M.D., professor in the Department of Medicine, and Karl Willert, Ph.D., professor in the Department of Cellular & Molecular Medicine at UC San Diego School of Medicine.